Patients with HR+ breast cancer often respond favorably to drugs such as exemestane and letrozole, which inhibit hormone production by blocking the enzyme aromatase, or to drugs such as tamoxifen and fulvestrant, which act directly on ER to block estradiol-dependent signaling. This evidence concerns the gene CYP19A1 and breast carcinoma.